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E R R A T U M
Erratum
Preinvasive and invasive ductal pancreatic cancer and its early
detection in the mouse
In the article by Hingorani et al. (Cancer Cell 4, pp. 437–450), there are several typographical
errors in the text regarding the citation of the figures.
On page 441, the sentence “In many of the older mice, the pancreata contained extensive ductal
lesions, and the acinar parenchyma was largely replaced by an intense stromal, or desmoplastic,
reaction comprised of inflammatory cells, fibroblasts, and collagen deposition (Figures 2I–2K)”
should instead refer to Figures 2I–2L.
Also on page 441, the sentence “Finally, we note that PanINs expressed only low levels of
PDX-1, which can nevertheless be discerned when compared to the lack of expression in
surrounding acini (Figures 2G and 2H) and to normal ducts in control animals (Figure 2I)” should
refer instead to Figure 3, and thus should read “Finally, we note that PanINs expressed only low
levels of PDX-1, which can nevertheless be discerned when compared to the lack of expression
in surrounding acini (Figures 3G and 3H) and to normal ducts in control animals (Figure 3I).”
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